Trial Profile
Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Renadirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 13 Jan 2021 Results published in Daiichi Sankyo Media Release
- 14 Dec 2020 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.